| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.15 | 0.06 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.07 | 0.06 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.06 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.056 | 0.06 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.06 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.059 | 0.06 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.075 | 0.06 |